| Immunogenomic landscape of hematological malignancies O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ... Cancer Cell 38 (3), 380-399. e13, 2020 | 138 | 2020 |
| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 127 | 2020 |
| HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017 | 89 | 2017 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 85 | 2022 |
| The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia A Kumar, M Kankainen, A Parsons, O Kallioniemi, P Mattila, CA Heckman BMC genomics 18, 1-13, 2017 | 62 | 2017 |
| Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ... Leukemia 33 (6), 1360-1372, 2019 | 55 | 2019 |
| Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017 | 54 | 2017 |
| Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia S Adnan Awad, M Kankainen, T Ojala, P Koskenvesa, S Eldfors, ... Blood advances 4 (3), 546-559, 2020 | 51 | 2020 |
| Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML R Karjalainen, M Liu, A Kumar, L He, D Malani, A Parsons, M Kontro, ... Leukemia 33 (10), 2548-2553, 2019 | 35 | 2019 |
| Hemap: an interactive online resource for characterizing molecular phenotypes across hematologic malignancies P Pölönen, J Mehtonen, J Lin, T Liuksiala, S Häyrynen, S Teppo, ... Cancer research 79 (10), 2466-2479, 2019 | 29 | 2019 |
| Allelic imbalance of recurrently mutated genes in acute myeloid leukaemia AMN Batcha, SA Bamopoulos, P Kerbs, A Kumar, V Jurinovic, ... Scientific reports 9 (1), 11796, 2019 | 14 | 2019 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022; 12: 388–401. doi: 10.1158/2159-8290 D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... CD-21-0410.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 10 | |
| Chimeric NUP98–NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia JL Kivioja, JM Lopez Martí, A Kumar, M Kontro, H Edgren, A Parsons, ... Leukemia & lymphoma 59 (3), 725-732, 2018 | 9 | 2018 |
| FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML J Kivioja, D Malani, A Kumar, M Kontro, A Parsons, O Kallioniemi, ... Scientific Reports 11 (1), 23565, 2021 | 7 | 2021 |
| KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia D Malani, B Yadav, A Kumar, S Potdar, M Kontro, M Kankainen, ... Leukemia 34 (10), 2780-2784, 2020 | 7 | 2020 |
| Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling A Murumägi, D Ungureanu, S Khan, A Hirasawa, M Arjama, K Välimäki, ... Cancer Research 79 (13_Supplement), 2945-2945, 2019 | 6 | 2019 |
| Comparison of structural and short variants detected by linked-read and whole-exome sequencing in multiple Myeloma A Kumar, S Adhikari, M Kankainen, CA Heckman Cancers 13 (6), 1212, 2021 | 5 | 2021 |
| Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients M Majumder, A Kumar, C Heckman, M Kankainen, S Pesonen, E Jäger, ... Journal for Immunotherapy of Cancer 2 (Suppl 3), 2014 | 3 | 2014 |
| Combined targeting of BET family proteins and BCL2 Is synergistic in acute myeloid leukemia cells overexpressing S100A8 and S100A9 R Karjalainen, M Liu, A Kumar, A Parsons, L He, DR Malani, M Kontro, ... Blood 132, 2634, 2018 | 2 | 2018 |
| Identification and clinical exploration of individualized targeted therapeutic approaches in acute myeloid leukemia patients by integrating drug response and deep molecular … D Malani, A Kumar, B Yadav, M Kontro, S Potdar, S Eldfors, J Saarela, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 854-854, 2017 | 2 | 2017 |
